logo-loader
Health
viewNuformix Plc

Nuformix PLC has 'validated its platform' as it works on 'immediate commercial opportunities'

Dan Gooding, chief executive of Nuformix (LON:NFX), caught up with Proactive London's Andrew Scott  soon after raising £1.25mln to help advance its pipeline of drugs.

Gooding says the fundraise strengthens its position as negotiations continue in Asia for its NXP2 asset.

Quick facts: Nuformix Plc

Price: 6.8 GBX

LSE:NFX
Market: LSE
Market Cap: £31.94 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Nuformix Plc named herein, including the promotion by the Company of Nuformix Plc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

'Watershed moment' for Nuformix as it reports positive results for lead...

Dan Gooding, chief executive of Nuformix (LON:NFX) caught up with Proactive's Andrew Scott after reporting positive results in its clinical study for the company's lead programme NXP001. Gooding says the drug – a treatment for chemotherapy-induced nausea – achieved bioequivalence to...

on 30/5/19

2 min read